Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.

Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, Yano T, Nakata K, Kimura Y, Abe K, Ohwada W, Miura T.

J Pharmacol Exp Ther. 2018 Dec 14. pii: jpet.118.253666. doi: 10.1124/jpet.118.253666. [Epub ahead of print]

2.

Translational regulation by miR-301b upregulates AMP deaminase in diabetic hearts.

Tatekoshi Y, Tanno M, Kouzu H, Abe K, Miki T, Kuno A, Yano T, Ishikawa S, Ohwada W, Sato T, Niinuma T, Suzuki H, Miura T.

J Mol Cell Cardiol. 2018 Jun;119:138-146. doi: 10.1016/j.yjmcc.2018.05.003. Epub 2018 May 4.

PMID:
29733818
3.

Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes.

Muratsubaki S, Kuno A, Tanno M, Miki T, Yano T, Sugawara H, Shibata S, Abe K, Ishikawa S, Ohno K, Kimura Y, Tatekoshi Y, Nakata K, Ohwada W, Mizuno M, Miura T.

Sci Rep. 2017 Jul 13;7(1):5311. doi: 10.1038/s41598-017-05667-5.

4.

Suppression of autophagic flux contributes to cardiomyocyte death by activation of necroptotic pathways.

Ogasawara M, Yano T, Tanno M, Abe K, Ishikawa S, Miki T, Kuno A, Tobisawa T, Muratsubaki S, Ohno K, Tatekoshi Y, Nakata K, Ohwada W, Miura T.

J Mol Cell Cardiol. 2017 Jul;108:203-213. doi: 10.1016/j.yjmcc.2017.06.008. Epub 2017 Jun 21.

PMID:
28647341

Supplemental Content

Loading ...
Support Center